A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Clinical trial NCT05669430 · RECRUITING

Trial details

NCT number: NCT05669430
Sponsor: GV20 Therapeutics
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult Refractory Cancer Endometrial Carcinoma (EC)Squamous Head and Neck Carcinoma pMMR/MSS Adenocarcinoma of the Colon or Rectum Cutaneous Melanoma Non-Small Cell Lung Cancer

Start date: 2023-03-23
Primary completion: 2026-12-15
Enrollment: 365

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.